Results from the second WHO external quality assessment for the molecular detection of respiratory syncytial virus, 2019-2020.
laboratory diagnostics and systems
respiratory diseases
strengthening laboratory capacity for infectious disease control
Journal
Influenza and other respiratory viruses
ISSN: 1750-2659
Titre abrégé: Influenza Other Respir Viruses
Pays: England
ID NLM: 101304007
Informations de publication
Date de publication:
01 2023
01 2023
Historique:
received:
16
08
2022
revised:
27
10
2022
accepted:
29
10
2022
entrez:
24
2
2023
pubmed:
25
2
2023
medline:
3
3
2023
Statut:
epublish
Résumé
External quality assessments (EQAs) for the molecular detection of human respiratory syncytial virus (RSV) are necessary to ensure the standardisation of reliable results. The Phase II, 2019-2020 World Health Organization (WHO) RSV EQA included 28 laboratories in 26 countries. The EQA panel evaluated performance in the molecular detection and subtyping of RSV-A and RSV-B. This manuscript describes the preparation, distribution, and analysis of the 2019-2020 WHO RSV EQA. Panel isolates underwent whole genome sequencing and in silico primer matching. The final panel included nine contemporary, one historical virus and two negative controls. The EQA panel was manufactured and distributed by the UK National External Quality Assessment Service (UK NEQAS). National laboratories used WHO reference assays developed by the United States Centers for Disease Control and Prevention, an RSV subtyping assay developed by the Victorian Infectious Diseases Reference Laboratory (Australia), or other in-house or commercial assays already in use at their laboratories. An in silico analysis of isolates showed a good match to assay primer/probes. The panel was distributed to 28 laboratories. Isolates were correctly identified in 98% of samples for detection and 99.6% for subtyping. The WHO RSV EQA 2019-2020 showed that laboratories performed at high standards. Updating the composition of RSV molecular EQAs with contemporary strains to ensure representation of circulating strains, and ensuring primer matching with EQA panel viruses, is advantageous in assessing diagnostic competencies of laboratories. Ongoing EQAs are recommended because of continued evolution of mismatches between current circulating strains and existing primer sets.
Sections du résumé
Background
External quality assessments (EQAs) for the molecular detection of human respiratory syncytial virus (RSV) are necessary to ensure the standardisation of reliable results. The Phase II, 2019-2020 World Health Organization (WHO) RSV EQA included 28 laboratories in 26 countries. The EQA panel evaluated performance in the molecular detection and subtyping of RSV-A and RSV-B. This manuscript describes the preparation, distribution, and analysis of the 2019-2020 WHO RSV EQA.
Methods
Panel isolates underwent whole genome sequencing and in silico primer matching. The final panel included nine contemporary, one historical virus and two negative controls. The EQA panel was manufactured and distributed by the UK National External Quality Assessment Service (UK NEQAS). National laboratories used WHO reference assays developed by the United States Centers for Disease Control and Prevention, an RSV subtyping assay developed by the Victorian Infectious Diseases Reference Laboratory (Australia), or other in-house or commercial assays already in use at their laboratories.
Results
An in silico analysis of isolates showed a good match to assay primer/probes. The panel was distributed to 28 laboratories. Isolates were correctly identified in 98% of samples for detection and 99.6% for subtyping.
Conclusions
The WHO RSV EQA 2019-2020 showed that laboratories performed at high standards. Updating the composition of RSV molecular EQAs with contemporary strains to ensure representation of circulating strains, and ensuring primer matching with EQA panel viruses, is advantageous in assessing diagnostic competencies of laboratories. Ongoing EQAs are recommended because of continued evolution of mismatches between current circulating strains and existing primer sets.
Identifiants
pubmed: 36824313
doi: 10.1111/irv.13073
pii: IRV13073
pmc: PMC9849090
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e13073Subventions
Organisme : World Health Organization
ID : 001
Pays : International
Organisme : Medical Research Council
ID : MR/R010161/1
Pays : United Kingdom
Informations de copyright
© 2023 The Authors. Influenza and Other Respiratory Viruses published by John Wiley & Sons Ltd.
Déclaration de conflit d'intérêts
No conflict of interest is declared by authors.
Références
Emerg Infect Dis. 2021 Jun;27(6):1-9
pubmed: 34013862
J Infect Dis. 2022 Mar 15;225(6):957-964
pubmed: 35030633
Osong Public Health Res Perspect. 2021 Oct;12(5):286-292
pubmed: 34719220
Lancet. 2022 May 28;399(10340):2047-2064
pubmed: 35598608
Eur Respir J. 2021 Oct 1;58(3):
pubmed: 33888523
Mol Biol Evol. 2008 Jul;25(7):1253-6
pubmed: 18397919
Influenza Other Respir Viruses. 2020 Nov;14(6):671-677
pubmed: 32730685
J Virol Methods. 2019 Sep;271:113676
pubmed: 31181218
Influenza Other Respir Viruses. 2020 May;14(3):274-285
pubmed: 32022426
Med Sci Monit. 2021 Jan 03;27:e929783
pubmed: 33388738
Pediatr Infect Dis J. 2021 Apr 1;40(4):e164-e166
pubmed: 33464015
J Virol Methods. 2021 Aug;294:114171
pubmed: 33984394
J Clin Virol. 2017 Mar;88:21-25
pubmed: 28107671
Virology. 1991 Jul;183(1):273-87
pubmed: 2053282
Mol Biol Evol. 2013 Apr;30(4):772-80
pubmed: 23329690
Bioinformatics. 2014 Nov 15;30(22):3276-8
pubmed: 25095880
PLoS One. 2010 Nov 30;5(11):e15098
pubmed: 21152047
Bioinformatics. 2003 Aug 12;19(12):1572-4
pubmed: 12912839
Mol Biol Evol. 2015 Jan;32(1):268-74
pubmed: 25371430
Euro Surveill. 2021 Jul;26(29):
pubmed: 34296673
Mol Biol Evol. 2016 Jul;33(7):1870-4
pubmed: 27004904
Influenza Other Respir Viruses. 2018 Sep;12(5):551-557
pubmed: 29722140
Nucleic Acids Res. 2004 Mar 19;32(5):1792-7
pubmed: 15034147